Recent European oncology drug approvals

Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

Swiss drug regulators have become the first to approve Novartis' Tasigna (nilotinib) for the treatment of patients with Ph+ chronic myeloid leukemia who are resistant or intolerant to imatinib (Gleevec)

Swiss drug regulators have become the first to approve Novartis' Tasigna (nilotinib) for the treatment of patients with Ph+ chronic myeloid leukemia who are resistant or intolerant to imatinib (Gleevec), based on phase II results (see page 26). The drug is under review by the US Food and Drug Administration (FDA).

The Swiss have also authorized Northwest Biotherapeutics' DCVax-Brain for the treatment of brain cancer. The company will be permitted to manufacture DCVax-Brain in the United States and make it available for patients at select centers in Switzerland. DCVax products are made by combining a patient's own dendritic cells with cancer biomarkers derived from or displayed by the tumor.

The European Union has recommended approval of Avastin (bevacizumab) as first-line therapy of advanced non-small-cell lung cancer, in combination with chemotherapy. The US FDA gave approval for this indication last October.

After Eli Lilly challenged an earlier denial, the UK's National Institute for Health and Clinical Excellence (NICE) has recommended that Alimta (pemetrexed) be made available for treatment of advanced inoperable malignant pleural mesothelioma. NICE originally did not recommend Alimta for this indication due to cost concerns.

Related Videos
Talha Badar, MBBS, MD, discussed ongoing trials in the treatment of chronic myeloid leukemia in chronic phase, as well as his hope for future therapies in the space.
Talha Badar, MBBS, MD, discussed how results from the phase 3 ASCEMBL study of asciminib will impact clinical practice in treating chronic myeloid leukemia in chronic phase.
Talha Badar, MBBS, MD, discussed the unmet needs in the treatment of chronic myeloid leukemia in chronic phase.
Talha Badar, MBBS, MD, discussed the results of the phase 3 ASCEMBL trial, demonstrating the superiority of asciminib versus bosutinib in patients with chronic myeloid leukemia in chronic phase.